Please Wait.....
Report
Alzheimer's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis 2023-2028
Market Report I 2023-02-02 I 244 Pages I Arizton Advisory & Intelligence
The global Alzheimer's disease therapeutics market is expected to grow at a CAGR of 12.19% from 2022-2028.
MARKET SUMMARY
According to Arizton's estimates, the prevalence of Alzheimer's disease was high in China, followed by U.S. and Japan in 2021. In the 8MM, the total prevalent cases increased from 29,460,996 in 2021 to 36,009,144 cases in 2028. The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market. According to the estimates, approximately 900,000 new patients are diagnosed annually in the US alone.
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory loss, cognitive impairment, and functional decline. During the early stages of the disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation, either by a home care professional or a family member. With rapidly increasing worldwide prevalence, the international medical community has identified Alzheimer's disease as a major global health threat. Significant efforts have been made to develop a new treatment, as current pharmacologic management is known only temporarily to improve symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area of opportunity exists for developing an effective pharmacologic approach in the global Alzheimer's disease therapeutics market.
a) Alzheimer's Disease Diagnosis
Several laboratory tests can diagnose Alzheimer's disease to assess memory impairment and other thinking skills, judge functional abilities, and identify behavior changes. The brain-imaging technologies most often used are Magnetic resonance imaging (MRI), Computerized tomography (CT), and Positron emission tomography (PET).
b) Alzheimer's Disease Treatment
The current competitive landscape in AD consists only of symptomatic treatments, of which there are currently seven approved medications: three ChEIs (donepezil, rivastigmine, and galantamine), one NMDA-R antagonist (memantine), one combination therapy (memantine/donepezil), and two A? A4 protein inhibitor (aducanumab and sodium oligomannate). In the global Alzheimer's disease therapeutics market, cholinesterase inhibitors are the major drugs available for Alzheimer's because the enzyme cholinesterase is a significant therapeutic target for Alzheimer's. Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments expected to occur within the next decade, could significantly affect how the disease is managed. Earlier disease detection may render the currently available therapies more useful, but until disease-modifying agents are introduced, the landscape will not change significantly.
ALZHEIMER'S DISEASE: CLINICAL TRIALS SCENARIO
The Alzheimer's disease therapeutics market portfolio contains a total of 151+ assets in various development phases. Most industry-sponsored drugs in active clinical development for Alzheimer's Disease are in the Phase II stage.
The clinical trial portfolio contains 139+ trials in various development phases. Most industry-sponsored drugs in active clinical development for Alzheimer's Disease are in the Phase II stage. The global pharmaceutical industry is steadily developing new drugs for Alzheimer's Disease, a Central Nervous System disorder. Moreover, North America boasts the highest number of ongoing clinical trials involving Alzheimer's Disease. Asia-Pacific and Europe are the other prominent regions involved in Alzheimer's Disease-related drug trials. Further, Eli Lilly and Company is the leading ongoing Alzheimer's Disease-related clinical trials sponsor in the Alzheimer's disease therapeutics market. Eisai Co Ltd, Roche Ltd, Cognition Therapeutics Inc, and Cassava Sciences Inc?are a few other notable sponsors involving Alzheimer's Disease.
MARKET TRENDS & DRIVERS
a) Launch of New Therapies
The USFDA approved biological drug candidates such as Aducanumab (Aduhelm) in 2021 for treating early Alzheimer's Disease. With Aduhelm being the biologic approved for Alzheimer's disease in 2021, there is a demand for biological therapies with novel MOAs, and many new classes of therapies are looking to enter the Alzheimer's disease therapeutics market over the next few years. The biologics such as amyloid beta inhibitors are making inroads into the Alzheimer's disease market owing to better clinical profiles and convenient patient dosing. Launching approved small molecules, and further uptake in biological therapies will lead to significant growth in the Alzheimer's Disease therapeutics market.
b) Increasing Prevalence of Alzheimer's Disease
The Alzheimer's disease therapeutics market has been witnessing considerable growth, which is attributed to the increasing prevalence of Alzheimer's Disease worldwide. According to the estimates, the prevalence of Alzheimer's Disease patients was 6.5 million in the United States in 2022.
c) High Investment in R&D Activities
Major players in the Alzheimer's disease therapeutics market are developing novel products and spending significantly on research and development, along with major acquisitions and collaborations to achieve a competitive edge over their counterparts. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.
SEGMENTATION ANALYSIS
1. Drug Class: The ACE inhibitors are expected to account for a significant share of the global Alzheimer's disease therapeutics market by drug class. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period. Recently approved biologic such as Aducanumab (Aduhelm) is expected to drive the global Alzheimer's disease therapeutics market during the forecast period.
Segmentation By Drug Class
- ACE Inhibitors
- NMDA Inhibitors
- Other Drug class
2. Gender Type: Among the gender type, women were expected to account for a significant share of the global Alzheimer's disease therapeutics market. The majority of the share is due to women's longer life expectancy.
Segmentation By Gender Type
- Men
- Women
3. Age Group: The global Alzheimer's disease therapeutics market by age group people is expected to be dominated by the 85 years & above age group. However, people 65 years & above are expected to be the fastest-growing segment during the study period.
Segmentation By Age Group
- 65-74 years
- 75-84 years
- 85 years & Above
4. Severity Type: Among the severity type, People with mild form are expected to account for a significant share of the global Alzheimer's Disease therapeutics market. In 2021, the incidence of Alzheimer's disease was 229,385 in the U.S., projected to grow significantly during the forecast period. However, people with moderate form are expected to be the fastest-growing segment during the forecast period.
Segmentation By Severity Type
- Mild
- Moderate
- Severe
GEOGRAPHICAL ANALYSIS
The U.S. dominates the global Alzheimer's disease therapeutics market by geography due to the rise in healthcare affordability in the U.S., the rise in knowledge and awareness amongst the people, and technological advancement in this region. However, China is expected to grow at a faster rate with a high CAGR in the global Alzheimer's disease therapeutics market due to the geriatric population's rise, awareness about disease management, and rising healthcare expenditure in the APAC region.
Segmentation By Geography
- North America
o US
- APAC
o China
o Japan
- Europe
o France
o Germany
o UK
o Italy
o Spain
COMPETITIVE LANDSCAPE
The current competitive landscape in AD consists only of symptomatic treatments, of which there are currently seven approved medications. The global Alzheimer's disease therapeutics market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating Alzheimer's Disease. The U.S. Food and Drug Administration (FDA) approved the amyloid beta antibody Adehulm (Adecanumab) for treating Alzheimer's Disease in 2021. This marked the arrival of biologics in this treatment landscape. Although generic products continue to capture significant Alzheimer's disease therapeutics market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.
The global Alzheimer's disease therapeutics market contains 151+ assets in various development phases. The emerging therapeutics being developed for Alzheimer's Disease include Lecanemab, Nilotinib, Remternetug, NE-3107, Bepranemab, Vafidemstat, Seltorexant, and many others. Launching these novel emerging drugs will shift the Alzheimer's Disease therapeutics paradigm shortly. With more than 151 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating Alzheimer's Disease.
Key Vendors
- Novartis AG
- AbbVie Inc (AbbVie)
- Biogen Inc (Biogen)
- Johnson & Johnson (J&J)
- Eisai Co Ltd (Eisai)
- Green Valley Pharmaceuticals
- UCB SA (UCB)
- KeifeRx
- Eli Lilly and Co (Lilly)
- BioVie Inc
- NeuroKine Therapeutics (NKT), LLC
Other Prominent Vendors
- Vaccinex, Inc.
- Alzinova AB
- Asceneuron SA
- Biohaven
- Denali
- Alzamend
Key Milestones in The Alzheimer's Disease Therapeutics Market:
a) In April 2022, Biogen Announced that the European Medicines Agency (EMA) had withdrawn its Marketing Authorization Application (MAA) for aducanumab to treat the early stages of Alzheimer's disease due to a lack of sufficient data.
b) In March 2022, Corium, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Adlarity (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of Alzheimer's Disease.
c) In June 2021, Biogen Announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Aduhelm (aducanumab-avwa) to treat early Alzheimer's disease. The approval is based on two Phase 3 clinical trialsEMERGE (Study 1) and ENGAGE (Study 2)in patients with early stages of Alzheimer's disease (mild cognitive impairment and mild dementia) with confirmed presence of amyloid pathology.
REPORT COVERS
- Detailed overview of Alzheimer's Disease, including disease definition, classification, diagnosis, and treatment pattern
- Overview of the global trends of Alzheimer's Disease in the eight major markets (8MM)
- Historical, current, and projected patient pool of Alzheimer's Disease in the eight major markets (8MM) for the 2019 2028 period
- Gender type, Drug Class, Age group, Severity type, and Geography type segmentations of Alzheimer's Disease in the eight major markets (8MM)
- Historical, current, and projected market size of Alzheimer's Disease in the eight major markets (8MM) for the 2019 2028 period
- In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
- Market share of the market players, company profiles, product specifications, and competitive landscape
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
- Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
- Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alzheimer's Disease across the complete product development cycle, including all clinical and non-clinical stages
- Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for Alzheimer's Disease across all clinical stages
- Coverage of dormant and discontinued pipeline projects along with the reasons across Alzheimer's Disease
- Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the Alzheimer's Disease space.
KEY QUESTIONS ANSWERED:
1. How big is the Alzheimer's disease therapeutics market?
2. What is the growth rate of the global Alzheimer's disease therapeutics market?
3. What are some significant trends in the Alzheimer's disease therapeutics market?
4. Who are the leading vendors operating in the global Alzheimer's disease therapeutics market?
5. Which region holds the most extensive global Alzheimer's disease therapeutics market share?
1. ALZHEIMER'S DISEASE OVERVIEW
1.1. Alzheimer's Disease - An Overview
2. ALZHEIMER'S DISEASE EPIDEMIOLOGY & OVERVIEW
2.1. 8MM: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.2. 8MM: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.3. 8MM: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.4. 8MM: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.5. 8MM: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.6. 8MM: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.7. 8MM: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.8. 8MM: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.9. 8MM: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.10. 8MM: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.11. US: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.12. US: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.13. US: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.14. US: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.15. US: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.16. US: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.17. US: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.18. US: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.19. US: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.20. US: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.21. China: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.22. China: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.23. China: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.24. China: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.25. China: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.26. China: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.27. China: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.28. China: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.29. China: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.30. China: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.31. Japan: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.32. Japan: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.33. Japan: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.34. Japan: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.35. Japan: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.36. Japan: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.37. Japan: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.38. Japan: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.39. Japan: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.40. Japan: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.41. Germany: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.42. Germany: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.43. Germany: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.44. Germany: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.45. Germany: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.46. Germany: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.47. Germany: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.48. Germany: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.49. Germany: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.50. Germany: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.51. UK: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.52. UK: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.53. UK: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.54. UK: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.55. UK: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.56. UK: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.57. UK: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.58. UK: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.59. UK: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.60. UK: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.61. France: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.62. France: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.63. France: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.64. France: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.65. France: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.66. France: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.67. France: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.68. France: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.69. France: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.70. France: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.71. Italy: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.72. Italy: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.73. Italy: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.74. Italy: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.75. Italy: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.76. Italy: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.77. Italy: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.78. Italy: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.79. Italy: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.80. Italy: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
2.81. Spain: Historic & Projected Volume of Incidence & Prevalence of Alzheimer's Disease
2.82. Spain: Comparative Analysis of Incidence & Prevalence of Alzheimer's Disease
2.83. Spain: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Disease type
2.84. Spain: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Severity type
2.85. Spain: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Age Group
2.86. Spain: Historic & Projected Volume of Incidence of Alzheimer's Disease cases by Gender type
2.87. Spain: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Disease type
2.88. Spain: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Severity type
2.89. Spain: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Age Group
2.90. Spain: Historic & Projected Volume of Prevalence of Alzheimer's Disease cases by Gender type
3. ALZHEIMER'S DISEASE MARKET SIZE & OVERVIEW
3.1. 8MM: Historic & Projected Revenue of Alzheimer's Disease
3.2. 8MM: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.3. 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.4. US: Historic & Projected Revenue of Alzheimer's Disease
3.5. US: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.6. US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.7. China: Historic & Projected Revenue of Alzheimer's Disease
3.8. China: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.9. China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.10. Germany: Historic & Projected Revenue of Alzheimer's Disease
3.11. Germany: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.12. Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.13. Japan: Historic & Projected Revenue of Alzheimer's Disease
3.14. Japan: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.15. Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.16. France: Historic & Projected Revenue of Alzheimer's Disease
3.17. France: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.18. France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.19. Italy: Historic & Projected Revenue of Alzheimer's Disease
3.20. Italy: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.21. Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.22. UK: Historic & Projected Revenue of Alzheimer's Disease
3.23. UK: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.24. UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
3.25. Spain: Historic & Projected Revenue of Alzheimer's Disease
3.26. Spain: Historic & Projected Revenue of Alzheimer's Disease Snapshot
3.27. Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
4. ALZHEIMER'S DISEASE MARKETED DRUGS OVERVIEW
4.1. Alzheimer's Disease Marketed Drugs - An Overview
4.2. Alzheimer's Disease Marketed Drugs - Summary
5. ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW
5.1. Alzheimer's Disease Pipeline Drugs - An Overview
5.2. Alzheimer's Disease Pipeline Drugs - Snapshot
5.3. Alzheimer's Disease Pipeline Drugs Overview & Snapshot - By Disease type
5.4. Alzheimer's Disease Pipeline Drugs Overview & Snapshot - By Development Phase
5.5. Alzheimer's Disease Pipeline Drugs Overview & Snapshot - By Route of Administration
5.6. Alzheimer's Disease Pipeline Drugs Overview & Snapshot - By Mechanism of Action
5.7. Alzheimer's Disease Pipeline Drugs Overview & Snapshot - By Molecule type
5.8. Alzheimer's Disease Pipeline Drugs Overview & Snapshot - By Geography type
6. ALZHEIMER'S DISEASE CLINICAL TRIALS OVERVIEW
6.1. Alzheimer's Disease Clinical Trials Overview Snapshot
6.2. Alzheimer's Disease Clinical Trials Overview - By Recruitment Status
6.3. Alzheimer's Disease Clinical Trials Overview - By Product type
6.4. Alzheimer's Disease Clinical Trials Overview - By Route of Administration
6.5. Alzheimer's Disease Clinical Trials Overview - By Molecule type
6.6. Alzheimer's Disease Clinical Trials Overview - By Geography type
7. ALZHEIMER'S DISEASE MARKET DYNAMICS
7.1. Alzheimer's Disease Therapeutics Market Drivers
7.2. Alzheimer's Disease Therapeutics Market Constraints
7.3. Alzheimer's Disease Therapeutics Market Trends
8. ALZHEIMER'S DISEASE COMPETITIVE LANDSCAPE
8.1. Alzheimer's Disease Competitive Landscape - Marketed Drugs
8.2. Key Company Profiles
8.3. Other Key Company Profiles
8.4. Competitive Scenario of Alzheimer's Disease therapeutics market
8.5. Key Company Profile Snapshot
8.6. Other Key Company Profile Snapshot
8.7. Alzheimer's Disease Competitive Landscape - Pipeline Drugs
8.8. Key Emerging Company Profiles
8.9. Other Key Emerging Company Profiles
8.10. Key Company Profile Snapshots
9. ALZHEIMER'S DISEASE MISCELLANEOUS
9.1. Key Tentative Drug Approvals Timeline
9.2. Key Regulatory Designations
9.3. Key Milestones
9.4. Deals & Collaborations
9.5. Inactive/Discontinued/Dormant Products
9.6. Unmet needs/Strategic Recommendations
10. APPENDIX
10.1. About Arizton
10.2. Research Methodology
10.3. List of Abbreviations
LIST OF EXHIBITS
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN 8 MAJOR MARKETS (2019 - 2021)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN 8 MAJOR MARKETS (2022 - 2028)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN US (2019 - 2028)
Exhibit 11: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN US (2019 - 2021)
Exhibit 12: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN US (2022 - 2028)
Exhibit 13: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN US (2019 - 2028)
Exhibit 14: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN US (2019 - 2028)
Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN US (2019 - 2028)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN US (2019 - 2028)
Exhibit 17: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN US (2019 - 2028)
Exhibit 18: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN US (2019 - 2028)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN CHINA (2019 - 2028)
Exhibit 20: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN CHINA (2019 - 2021)
Exhibit 21: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN CHINA (2022 - 2028)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN CHINA (2019 - 2028)
Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN CHINA (2019 - 2028)
Exhibit 24: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN CHINA (2019 - 2028)
Exhibit 25: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN CHINA (2019 - 2028)
Exhibit 26: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN CHINA (2019 - 2028)
Exhibit 27: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN CHINA (2019 - 2028)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN JAPAN (2019 - 2028)
Exhibit 29: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN JAPAN (2019 - 2021)
Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN JAPAN (2022 - 2028)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN JAPAN (2019 - 2028)
Exhibit 32: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN JAPAN (2019 - 2028)
Exhibit 33: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN JAPAN (2019 - 2028)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN JAPAN (2019 - 2028)
Exhibit 35: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN JAPAN (2019 - 2028)
Exhibit 36: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN JAPAN (2019 - 2028)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN GERMANY (2019 - 2028)
Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN GERMANY (2019 - 2021)
Exhibit 39: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN GERMANY (2022 - 2028)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN GERMANY (2019 - 2028)
Exhibit 41: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN GERMANY (2019 - 2028)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN GERMANY (2019 - 2028)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN GERMANY (2019 - 2028)
Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN GERMANY (2019 - 2028)
Exhibit 45: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN GERMANY (2019 - 2028)
Exhibit 46: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN UK (2019 - 2028)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN UK (2019 - 2021)
Exhibit 48: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN UK (2022 - 2028)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN UK (2019 - 2028)
Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN UK (2019 - 2028)
Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN UK (2019 - 2028)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN UK (2019 - 2028)
Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN UK (2019 - 2028)
Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN UK (2019 - 2028)
Exhibit 55: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN FRANCE (2019 - 2028)
Exhibit 56: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN FRANCE (2019 - 2021)
Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN FRANCE (2022 - 2028)
Exhibit 58: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN FRANCE (2019 - 2028)
Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN FRANCE (2019 - 2028)
Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN FRANCE (2019 - 2028)
Exhibit 61: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN FRANCE (2019 - 2028)
Exhibit 62: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN FRANCE (2019 - 2028)
Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN FRANCE (2019 - 2028)
Exhibit 64: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN ITALY (2019 - 2028)
Exhibit 65: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN ITALY (2019 - 2021)
Exhibit 66: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN ITALY (2022 - 2028)
Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN ITALY (2019 - 2028)
Exhibit 68: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN ITALY (2019 - 2028)
Exhibit 69: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN ITALY (2019 - 2028)
Exhibit 70: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN ITALY (2019 - 2028)
Exhibit 71: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN ITALY (2019 - 2028)
Exhibit 72: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN ITALY (2019 - 2028)
Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN SPAIN (2019 - 2028)
Exhibit 74: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN SPAIN (2019 - 2021)
Exhibit 75: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER'S DISEASE IN SPAIN (2022 - 2028)
Exhibit 76: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN SPAIN (2019 - 2028)
Exhibit 77: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN SPAIN (2019 - 2028)
Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN SPAIN (2019 - 2028)
Exhibit 79: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY SEVERITY TYPE IN SPAIN (2019 - 2028)
Exhibit 80: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY AGE GROUP IN SPAIN (2019 - 2028)
Exhibit 81: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER'S DISEASE BY GENDER TYPE IN SPAIN (2019 - 2028)
Exhibit 82: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2019 - 2028)
Exhibit 83: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2019 - 2021)
Exhibit 84: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2022 - 2028)
Exhibit 85: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2022 - 2028)
Exhibit 86: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2022 - 2028)
Exhibit 87: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY IN 8 MAJOR MARKETS (2022 - 2028)
Exhibit 88: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN US (2022 - 2028)
Exhibit 89: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN US (2019 - 2021)
Exhibit 90: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN US (2022 - 2028)
Exhibit 91: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN US (2022 - 2028)
Exhibit 92: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN US (2022 - 2028)
Exhibit 93: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY IN US (2022 - 2028)
Exhibit 94: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN CHINA (2022 - 2028)
Exhibit 95: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN CHINA (2019 - 2021)
Exhibit 96: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2022 - 2028)
Exhibit 97: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2022 - 2028)
Exhibit 98: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2022 - 2028)
Exhibit 99: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY IN CHINA (2022 - 2028)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GERMANY (2022 - 2028)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2019 - 2021)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2022 - 2028)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2022 - 2028)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2022 - 2028)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN GERMANY (2022 - 2028)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN JAPAN (2022 - 2028)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2019 - 2021)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2022 - 2028)
Exhibit 109: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2022 - 2028)
Exhibit 110: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2022 - 2028)
Exhibit 111: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN JAPAN (2022 - 2028)
Exhibit 112: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN FRANCE (2022 - 2028)
Exhibit 113: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2019 - 2021)
Exhibit 114: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2022 - 2028)
Exhibit 115: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2022 - 2028)
Exhibit 116: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2022 - 2028)
Exhibit 117: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN FRANCE (2022 - 2028)
Exhibit 118: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN ITALY (2022 - 2028)
Exhibit 119: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN ITALY (2019 - 2021)
Exhibit 120: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2022 - 2028)
Exhibit 121: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2022 - 2028)
Exhibit 122: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2022 - 2028)
Exhibit 123: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY IN ITALY (2022 - 2028)
Exhibit 124: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN UK (2022 - 2028)
Exhibit 125: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN UK (2019 - 2021)
Exhibit 126: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN UK (2022 - 2028)
Exhibit 127: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN UK (2022 - 2028)
Exhibit 128: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN UK (2022 - 2028)
Exhibit 129: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN UK (2022 - 2028)
Exhibit 130: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN SPAIN (2022 - 2028)
Exhibit 131: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2019 - 2021)
Exhibit 132: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2022 - 2028)
Exhibit 133: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2022 - 2028)
Exhibit 134: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2022 - 2028)
Exhibit 135: HISTORIC & PROJECTED REVENUE OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN SPAIN (2022 - 2028)
Exhibit 136: PIPELINE DRUGS OVERVIEW IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
Exhibit 137: ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 138: ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 139: ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 140: ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 141: ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 142: ALZHEIMER'S DISEASE PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 143: ALZHEIMER'S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 144: ALZHEIMER'S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 145: ALZHEIMER'S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 146: ALZHEIMER'S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 146: ALZHEIMER'S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 147: ALZHEIMER'S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 148: COMPETITIVE ASSESSMENT OF ALZHEIMER'S DISEASE THERAPEUTICS MARKET
LIST OF TABLES
Table 1: KEY MARKET DRIVERS IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
Table 2: KEY MARKET CONSTRAINTS IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
Table 3: KEY MARKET TRENDS IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN ALZHEIMER'S DISEASE
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN ALZHEIMER'S DISEASE
Table 6: KEY MILESTONES IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
Table 7: KEY DEALS & COLLABORATIONS IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN ALZHEIMER'S DISEASE THERAPEUTICS MARKET
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security